Skip to main content
DeutschDE
European Commission logo print header

MAnufacturing process for Cold-chain Independent VIrosome-based VAccines

Ziel

MACIVIVA is a highly interdisciplinary consortium among well established and innovative SMEs with scientific excellence and complementary industrial world-leading experts with unique expertise and know-how in virosome technology, spray and freeze drying, large scale manufacturing and packaging. MACIVIVA will pave the path to other large scale thermostable nanopharmaceuticals products for therapeutic and prophylactic vaccines and other potential applications for direct application by non-invasive routes.
Liquid products are inherently prone to physical and/or chemical modifications and degradations. Solid vaccine dosage formats (e.g. powder) may prevent molecular motion and shear-induced degradation, and slow down degradation involving water and oxygen radicals, resulting in improved stability and enhanced shelf-life of vaccines. The cold chain storage is still fundamental for preserving the bioactivity of most liquid and freeze-dried vaccines, and a reconstitution step prior to administration is required for freeze dried vaccines that are usually administered intramuscularly or subcutaneously. These reconstituted freeze dried vaccines harbor important instability and must be used within hours and kept refrigerated. Because most liquid and reconstituted freeze-dried vaccines are susceptible to degradations, it may affect the immunological properties of the immunogens, with unwanted immune responses or insufficient immune protection.
For addressing liquid virosome-based vaccine instability and improving their shelf-life outside the cold chain, MACIVIVA will explore new galenic vaccine formulations through careful screening of excipients, stabilization and drying methods for generating new vaccine solid forms that can be easily self-administered. Robust “universal” manufacturing processes for upscale production of virosome dried powder for the non-invasive intranasal, oral and sublingual routes should be achieved by month 42.

Wissenschaftliches Gebiet

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

H2020-NMP-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-NMP-PILOTS-2014

Finanzierungsplan

RIA - Research and Innovation action

Koordinator

MYMETICS BV
Netto-EU-Beitrag
€ 1 755 073,75
Adresse
J H OORTWEG 21
2333 CH LEIDEN
Niederlande

Auf der Karte ansehen
KMU

Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).
Ja
Region
West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 1 755 073,75

Beteiligte (5)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 9 August 2022

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/646122/de

European Union, 2024